LennardMS. Genetic polymorphism of sparteine/debrisoquin oxidation: A reappraisal. Pharmacol Toxicol1990; 67: 273–83.
2.
Van AckerSAKoymansLDonneOpdenKelderGMKoppleMVermeulenNPE. Mapping the active site of cytochrome P450IID1 (abstract). Pharmaceut Weekblad1990; 12 (suppl B):B9.
3.
TurgeonJEvansWERellingMVWilkinsonGRRodenDM. Phenotypic debrisoquin 4-hydroxylase activity among extensive metabolizers is unrelated to genotype as determined by the Xba-I restriction fragment length polymorphism. Br J Clin Pharmacol1991; 32: 283–8.
4.
BoobisARMurraySHampdenCEDaviesDS. Genetic polymorphism in drug oxidation: In vitro studies of human debrisoquin 4-hydroxylase and bufuralol l-hydroxylase activities. Biochem Pharmacol1985; 34: 65–71.
5.
DayerPLeemannTStriberniR. Dextromethorphan O-demethylation in liver microsomes as a prototype reaction to monitor cytochrome P-450 db1 activity. Clin Pharmacol Ther1989; 54: 34–40.
6.
HaefeliWEBargetziMJFollathFMeyerUA. Potent inhibition of cytochrome P450IID6 (debrisoquin 4-hydroxylase) by flecainide in vitro and in vivo. J Cardiovasc Pharmacol1990; 15: 776–9.
7.
RellingMVCherrieJSchellJPetrosWPMeyerWHEvansWE. Lower prevalence of the debrisoquin oxidative poor metabolizer phenotype in American black versus white subjects. Clin Pharmacol Ther1991; 50: 308–13.
8.
DesmeulesJDayerPGasconM-PMagistrisM. Impact of genetic and environmental factors on codeine analgesia (abstract). Clin Pharmacol Ther1989; 45: 122.
9.
BrosenK. Recent developments in hepatic drug oxidation. Implications for clinical pharmacokinetics. Clin Pharmacokinet1990; 18: 220–39.
LewisRVRamsayLEJacksonPRYeoWWLennardMSTuckerGT. Influence of debrisoquin oxidation phenotype on exercise tolerance and subjective fatigue after metoprolol and atenolol in healthy subjects. Br J Clin Pharmacol1991; 31: 391–8.
12.
LeeJTKroemerHKSilbersteinDJFunck-BrentanoCLineberryMDWoodAJJ. The role of genetically determined polymorphic drug metabolism in the beta-blockade produced by propafenone. N Engl J Med1990; 322: 1764–8.
13.
LennardMSTuckerGTWoodsHF. Inborn “errors” of drug metabolism: Pharmacokinetics and clinical implications. Clin Pharmacokinet1990; 19: 257–63.
14.
KupferAPreisigR. Pharmacogenetics of mephenytoin: A new drug hydroxylation polymorphism in man. Eur J Clin Pharmacol1984; 26: 753–9.
15.
WedlundPJAslanianWSMcAllisterWSWilkinsonGRBranchRA. Mephenytoin hydroxylation deficiency in Caucasians: Frequency of a new oxidative drug metabolism polymorphism. Clin Pharmacol Ther1984; 36: 773–80.
16.
BertilssonLBaillieTAReviriegoJ. Factors influencing the metabolism of diazepam. Pharmacol Ther1990; 45: 85–91.
17.
BertilssonLHenthornTKSanzETybringGSaweJVillenT. Importance of genetic factors in the regulation of diazepam metabolism: Relationship to S-mephenytoin, but not debrisoquin hydroxylation phenotype. Clin Pharmacol Ther1989; 45: 348–55.
18.
InabaTJurimaMMahonWAKalowW. In vitro inhibition studies of two isozymes of human liver cytochrome P-450: Mephenytoin hydroxylase and sparteine monooxygenase. Drug Metab Dispos1985; 13: 443–8.
19.
KumanaCRLauderIJChanMKoWLinHJ. Differences in diazepam pharmacokinetics in Chinese and white Caucasians. Eur J Clin Pharmacol1987; 32: 211–5.
20.
AnderssonTRegardhC-GDahl-PuustinenM-LBertilssonL. Slow omeprazole metabolizers are also poor S-mephenytoin hydroxylators. Ther Drug Monit1990; 12: 415–6.
21.
AnderssonTCederbergCEdvardssonGHeggelundALundborgP. Effect of omeprazole on diazepam metabolism in slow versus normal rapid metabolizers of omeprazole. Clin Pharmacol Ther1990; 47: 79–85.
22.
WardSAWalleTWalleUKWilkinsonGRBranchRA. Propranolol's metabolism is determined by both mephenytoin and debrisoquin hydroxylase activities. Clin Pharmacol Ther1989; 45: 72–9.
23.
HallSDGuengerichFPBranchRAWilkinsonGR. Characterization and inhibition of mephenytoin hydroxylase activity in human liver microsomes. J Pharmacol Ther1987; 240: 216–22.
24.
SkjelboEBrosenKHallasJGramLF. The mephenytoin oxidation polymorphism is partially responsible for the N-demethylation of imipramine. Clin Pharmacol Ther1991; 49: 18–23.
25.
BrosenKOttonSVGramLF. Imipramine demethylation and hydroxylation: Impact of the sparteine oxidation phenotype. Clin Pharmacol Ther1986; 40: 543–9.
26.
HelsbyNAWardSAHowellsREBreckenridgeAM. In vitro metabolism of the biguanide antimalarials in human liver microsomes: Evidence for a role of the mephenytoin hydroxylase enzyme. Br J Clin Pharmacol1990; 30: 287–91.
27.
HelsbyNAWardSAEdwardsGHowellsREBreckenridgeAM. The pharmacokinetics and activation of proguanil in man: Consequences of variability in drug metabolism. Br J Clin Pharmacol1990; 30: 593–8.
28.
WardSAHelsbyNASkjelboEBrosenKBreckenridgeAM. The activation of the biguanide antimalarial proguanil co-segregates with the mephenytoin oxidation polymorphism—a panel study. Br J Clin Pharmacol1991; 31: 689–92.
29.
AtibaJOBlaschkeTFWilkinsonGR. Effects of ketoconazole on the polymorphic 4-hydroxylations of S-mephenytoin and debrisoquin. Br J Clin Pharmacol Ther1989; 28: 161–5.
30.
ZhouHHAnthonyLDWoodAJJWilkinsonGR. Induction of polymorphic 4î-hydroxylation of S-mephenytoin by rifampicin. Br J Clin Pharmacol1990; 30: 471–5.
31.
CombalbertJFabreIFabreGDaletIDerancourtJCanoJP. Metabolism of cyclosporin A. IV. Purification and identification of the rifampicin-inducible human liver cytochrome P-450 (cyclosporin A oxidase) as a product of P-450IIIA gene subfamily. Drug Metab Disp1989; 17: 197–207.
32.
PichardLFabreIFabreGDomergueJAubertBSMouradG. Cyclosporin A drug inducers and inhibitors of cytochrome P-450 (cyclosporin A oxidase) in primary cultures of human hepatocytes and in liver microsomes. Drug Metab Dispos1990; 18: 595–606.
33.
BackDJTjiaJF. Comparative effects of the antimycotic drugs ketoconazole, fluconazole, itraconazole and terbinafine on the metabolism of cyclosporin by human liver microsomes. Br J Clin Pharmacol1991; 32: 624–6.
34.
FritzSLindnerWRootsIFreyBMKupferA. Sterochemistry of aromatic DPH hydroxylation in various drug hydroxylation phenotypes in humans. J Pharmacol Exp Ther1987; 241: 615–22.
35.
SchellensJHMVan der WartJHFBreimerDD. Relationship between mephenytoin oxidation polymorphism and DPH, methylphenytoin and phenobarbitone hydroxylation assessed in a phenotyped panel of healthy subjects. Br J Clin Pharmacol1990; 29: 665–71.
36.
DoeckeCJVeroneseMEPondSMMinersJOBirkettDJSansomLN. Relationship between DPH and tolbutamide hydroxylations in human liver microsomes. Br J Clin Pharmacol1991; 31: 125–30.
37.
VeroneseMEMacKenziePIDoeckeCJMcManusMEMinersJOBirkettDJ. Tolbutamide and phenytoin hydroxylations by cDNA-expressed human liver cytochrome P4502C9. Biochem Biophys Res Commun1991; 175: 1112–8.
38.
RellingMVAoyamaTGonzalezFJMeyerUA. Tolbutamide and mephenytoin hydroxylation by human cytochrome P450s in the CYP-2C subfamily. J Pharmacol Exp Ther1990; 252: 442–7.
39.
SrivastavaPKYunC-HBeaunePHGedCGuengerichFP. Separation of human liver microsomal tolbutamide hydroxylase and (S)-mephenytoin 4î-hydroxylase cytochrome P-450 enzymes. Molec Biol1991; 40: 69–79.
40.
LadonaMGLindstromBThyrCDun-RenPRaneA. Differential foetal development of the O- and N-demethylation of codeine and dextromethorphan in man. Br J Clin Pharmacol1991; 32: 295–302.
